CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
about
CCL3L1-CCR5 Genotype Improves the Assessment of AIDS Risk in HIV-1-Infected IndividualsWhen to start antiretroviral therapy: as soon as possibleIncomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsImmune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.CD4 count slope and mortality in HIV-infected patients on antiretroviral therapy: multicohort analysis from South AfricaCombined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients.CD4+ cells recovery in HIV positive patients with severe immunosuppression at HAART initiation at Centre Medico-Social Cor-Unum, KigaliTrends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational DatabasePrevalence and risk factors of poor immune recovery among adult HIV patients attending care and treatment centre in northwestern Tanzania following the use of highly active antiretroviral therapy: a retrospective study.Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.Effect of early versus deferred antiretroviral therapy for HIV on survival.Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTIMulti-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.Prevalence and Risk Factors of Mortality among Adult HIV Patients Initiating ART in Rural Setting of HIV Care and Treatment Services in North Western Tanzania: A Retrospective Cohort StudyConsistency of state statutes with the Centers for Disease Control and Prevention HIV testing recommendations for health care settings.Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy.Antiretroviral therapy in the clinicUnderstanding people who have never received HIV medical care: a population-based approach.Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.How HIV treatment could result in effective preventionAge-related changes in plasma concentrations of the HIV protease inhibitor lopinavir.Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa.Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa.Guidance on vaccination of HIV-infected children in Europe.Antiretroviral therapy for tuberculosis control in nine African countries.Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: a cohort study.Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy.Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infectionThe economic burden of late entry into medical care for patients with HIV infection.Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort.Poor immune reconstitution in HIV-infected patients associates with high percentage of regulatory CD4+ T cells.Monitoring Antiretroviral Therapy in HIV-Infected Children in Resource-Limited Countries: A Tale of Two EpidemicsImpaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohortIncomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.Among patients with sustained viral suppression in a resource-limited setting, CD4 gains are continuous although gender-based differences occur.Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria.Restoration of CMV-specific-CD4 T cells with ART occurs early and is greater in those with more advanced immunodeficiency.
P2860
Q19028101-1825AA37-3B24-447C-B68B-987D2254308FQ27006767-7F328B92-2E85-47C2-83A5-533DEF6D13FCQ27021524-45875647-B9D3-4A82-B80F-CA97CC3F3D4CQ27687272-514575E8-F34C-4BCC-A211-1C7239F351E5Q28703565-D75A25E8-84E1-4088-BD70-70E56AED0CFBQ31131058-3A8711AC-56EF-485E-8A25-0A0566A08A48Q33583499-1AB6B88E-BCDF-41EC-BB8C-784EA37918E0Q33779622-5E0E6965-23C0-4F76-9C32-129130ACE6E1Q33781469-6692E81B-6A48-4495-A7CF-C954E2864E22Q33782796-CA60A0C7-AC7D-4DD6-99B9-AA18AB4A8745Q33789114-CC7004C1-CE60-4B17-B525-E1DF60787063Q33803473-A417075E-DA0E-4919-A4A7-55E5AC74A240Q33846390-685BD39B-7BC7-4005-AC27-4956458E13F7Q33862338-009735C4-AAA0-4EA2-8F6F-82C87088F5FEQ33870261-A0738169-1664-4C0D-B846-B2E12DF6475DQ33873507-83CF6D19-7114-4E87-9D0B-382D7632307AQ33877347-901B219F-A7D8-4034-AD36-8710077E6563Q33901416-E26FE365-4FC2-4CB7-A407-6D1EE0B5A58DQ33933071-6E223850-B32E-4E13-8644-AEFB30132C80Q34065045-7E64E802-35C5-4B04-B7EF-E8965796C835Q34090397-1BBAAB31-9F24-4ABC-9001-63E07F60DFAFQ34100187-01F2C7BF-9EF0-4F31-A753-D9708118E31FQ34126302-353651A3-F2CB-439B-A67A-DBAF8AC3B5D9Q34163380-E8078F22-C6CE-4810-8D29-5B0A20DC34E6Q34170487-7EEB9A8A-3334-4197-9AB2-E90E95EC3170Q34251138-BA7F0030-3B52-450B-B574-E1B5AA2464D8Q34320245-02B83C92-EA38-4083-9E25-61E2A0163A92Q34332293-C90BB43F-7E92-4B86-AA10-980A94C6945FQ34395892-7F5DE2C8-C89B-4B70-B468-EFC2EAD4D1DDQ34477711-14E78DD0-770B-43F6-AB9A-3EF04BC586E3Q34497355-ECDCC7C2-A9DA-4BC7-BCA5-1FE72F4058EEQ34546011-3FC25852-A9A9-459F-9375-AC56F53CCCFAQ34569335-B2518547-D028-4624-A21B-A6B3895D4FBBQ34600441-F565840C-3216-40EC-8D21-35F3BA737BC2Q34734797-414C7D35-9834-4E95-906B-F22D3CD58132Q34779237-67898575-121D-4C25-A833-77C8218736F4Q34937231-EDF338E1-6146-4EB8-B524-0DBEA8A92E5CQ34981015-991B6B8C-4B02-4659-81B7-3C76658A51BAQ34986921-0343808C-BADE-4A44-B7F0-8569A6F35F8EQ35018886-8FDAA4BC-5838-46B9-B2DC-351866F6E781
P2860
CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
CD4+ cell count 6 years after ...... stained virologic suppression.
@en
CD4+ cell count 6 years after ...... stained virologic suppression.
@nl
type
label
CD4+ cell count 6 years after ...... stained virologic suppression.
@en
CD4+ cell count 6 years after ...... stained virologic suppression.
@nl
prefLabel
CD4+ cell count 6 years after ...... stained virologic suppression.
@en
CD4+ cell count 6 years after ...... stained virologic suppression.
@nl
P2860
P356
P1476
CD4+ cell count 6 years after ...... stained virologic suppression.
@en
P2093
Jeanne C Keruly
Richard D Moore
P2860
P304
P356
10.1086/510746
P407
P577
2006-12-20T00:00:00Z